Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Jul 16:12:20.
doi: 10.1186/1471-2415-12-20.

High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study

Mansing Ratanasukon  1 , Patama Bhurayanontachai, Pichai Jirarattanasopa
Affiliations
Randomized Controlled Trial

High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study

Mansing Ratanasukon et al. BMC Ophthalmol. .

Abstract

Background: To determine the efficacy of high-dose antioxidants in the acute stage of central serous chorioretinopathy (CSC).

Methods: This was a randomized placebo-controlled study. The patients with acute CSC (onset within 6 weeks) were randomized to receive either high-dose antioxidant tablets (study group A) or placebo tablets (control group B) for 3 months or until the complete resolution of subretinal fluid. After 3 months, additional treatment with laser or photodynamic therapy (PDT) was considered if any fluorescein leakage persisted. The outcomes measured were the changes in visual acuity (VA) and central macular thickness (CMT), the number of patients with subretinal fluid at each follow-up time, the number of patients with fluorescein leakage at the end of the 3rd month and patients who received additional treatments.

Results: Fifty-one of 58 patients (88%) completed the follow-up criteria. The baseline demographic data were comparable in both groups. At the end of the 3rd month, the VA and CMT showed no statistical difference between the groups but the patients in group A has less fluorescein leakage and additional treatments than in group B (p = 0.027 and 0.03).

Conclusion: The high-dose antioxidants for acute CSC did not show any benefits in VA and CMT. However, the drugs might decrease the chance for fluorescein leakage and additional treatments at the end of the 3rd month.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The patient with central serous chorioretinopathy showed typical inkblot leakage in the early phase (left) and late phase (right) from fluorescein angiography.
Figure 2
Figure 2
The trial profile CSC = central serous chorioretinopathy,PDT = photodynamic therapy Study group (group A): the group received antioxidant tabletsControl group (group B): the group received placebo tablets.
Figure 3
Figure 3
The mean visual acuity (VA) at each follow-up time between the study and control group. Study group (group A): the group received antioxidant tablets, Control group (group B): the group received placebo tablets, VA = visual acuity, logMAR = logarithm of minimum angle of resolution.
Figure 4
Figure 4
The mean central macular thickness (CMT) at each follow-up time between the study and control group. Study group (group A): the group received antioxidant tablets, Control group (group B): the group received placebo tablets, CMT = central macular thickness.
See this image and copyright information in PMC

References

    1. Klais CM, Ober MD, Ciardella AP, Yannuzzi LA. In: Retina vol II. 4th. Ryan SJ, editor. Mosby, St Louis; 2006. Central serous chorioretinopathy; pp. 1135–1161.
    1. Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow up of central serous chorioretinopathy. Br J Ophthalmol. 1984;68:815–820. doi: 10.1136/bjo.68.11.815. - DOI - PMC - PubMed
    1. Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL. et al.Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128:63–68. doi: 10.1016/S0002-9394(99)00075-6. - DOI - PubMed
    1. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: A case–control study. Ophthalmology. 2004;111:244–249. doi: 10.1016/j.ophtha.2003.09.024. - DOI - PubMed
    1. Loo RH, Scott IU, Flynn HW, Gass JD, Murray TG, Lewis ML. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19–24. doi: 10.1097/00006982-200202000-00004. - DOI - PubMed

Publication types